1CM
KURA icon

1492 Capital Management’s Kura Oncology KURA Stock Holding History

1492 Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.95M Buy
486,123
+33,485
+7% +$288K 1.5% 20
2025
Q4 		$4.7M Buy
452,638
+6,998
+2% +$73.4K 1.8% 19
2025
Q3 		$3.94M Buy
445,640
+21,693
+5% +$155K 1.6% 23
2025
Q2 		$2.45M Sell
423,947
-5,799
-1% -$35.5K 1.13% 30
2025
Q1 		$2.84M Buy
429,746
+87,148
+25% +$679K 1.53% 21
2024
Q4 		$2.98M Buy
342,598
+269,374
+368% +$3.88M 1.42% 27
2024
Q3 		$1.43M Buy
73,224
+486
+0.7% +$9.85K 0.71% 44
2024
Q2 		$1.5M Sell
72,738
-120
-0.2% -$2.47K 0.85% 41
2024
Q1 		$1.55M Sell
72,858
-28,642
-28% -$557K 0.87% 41
2023
Q4 		$1.46M Buy
101,500
+1,034
+1% +$10.2K 0.83% 46
2023
Q3 		$916K Hold
100,466
– – 0.59% 61
2023
Q2 		$1.06M Sell
100,466
-47
-0% -$556 0.62% 54
2023
Q1 		$1.23M Sell
100,513
-33
-0% -$412 0.76% 52
2022
Q4 		$1.25M Buy
100,546
+60,382
+150% +$878K 0.8% 40
2022
Q3 		$549K Sell
40,164
-9
-0% -$139 0.4% 76
2022
Q2 		$736K Buy
+40,173
New +$578K 0.48% 69

Other funds holding KURA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

1492 Capital Management's KURA Position: Q1 2026 in Review

1492 Capital Management increased its Kura Oncology (KURA) stake by 7.4% in Q1 2026, buying an estimated $288K and bringing the position to 486,123 shares worth $3.95M. The position accounts for 1.5% of the portfolio, ranked #20.

1492 Capital Management first reported a position in KURA in Q2 2022 and has held it in 16 quarters since. The position peaked at $4.7M in Q4 2025. 220 funds tracked by Wall St. Rank hold KURA as of Q1 2026.

  • 1492 Capital Management held 486,123 shares of Kura Oncology worth $3.95M as of Q1 2026.
  • 1492 Capital Management bought 33,485 Kura Oncology shares in Q1 2026, an estimated $288K.
  • Kura Oncology made up 1.5% of 1492 Capital Management's portfolio in Q1 2026, its #20 holding.
  • 1492 Capital Management first reported a position in Kura Oncology in Q2 2022 and has held it in 16 quarters since.
  • 1492 Capital Management's Kura Oncology position peaked at $4.7M in Q4 2025.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q1 2026.

Based on 1492 Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.